Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer
All-Comers Approach Disappoints
Executive Summary
Metastatic prostate cancer continues to evade the checkpoint inhibitor class but Merck is not giving up on an area where overall survival remains limited.
You may also be interested in...
Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal
The Finnish group has concluded an extensive search to partner its first-in-class CYP11A1 inhibitor, banking an impressive $290m upfront fee for the Phase II drug which is being evaluated for metastatic castration-resistant prostate cancer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: clinical setbacks in melanoma and prostate cancer; Chinese pharma firms face US listing pressures; Eisai hands Aduhelm to Biogen; and Scrip Asks what 2022 holds for digital and telehealth.
Speculation Grows On Potential Big Pharma Buyout Of Mirati
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.